Boston Scientific’s Obsidio Embolic Posts Clean 30-Day Results in Company-Sponsored Registry
A Boston Scientific-sponsored registry of 125 patients at 19 U.S. hospitals reports complete target-vessel occlusion and no rebleeding at 30 days with the Obsidio embolic. The single-arm design, company sponsorship and short follow-up limit what the results can show about the device.
Medtronic to Buy Contego Medical for $380 Million, Days After FDA Approves Its Carotid System
Medtronic plans to buy Contego Medical for $380 million plus undisclosed contingent payments. The deal adds a carotid stenting system with a built-in filter that the FDA approved days earlier, setting up direct competition with Boston Scientific in the growing field of transcarotid revascularization.